Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma

Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma

Summary: Metabolic-dysfunction-associated steatotic liver disease (MASLD) is becoming a leading cause of end-stage liver disease globally. Metabolic-dysfunction-associated steatohepatitis (MASH) represents a progressive inflammatory manifestation of MASLD. MASH underlies a versatile and dynamic infl...

Full description

Bibliographic Details
Main Authors:	Han Wang, Allan Tsung, Lopa Mishra, Hai Huang
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	EBioMedicine
Subjects:	Regulatory T cell Metabolic-dysfunction-associated steatotic liver disease Metabolic-dysfunction-associated steatohepatitis Hepatocellular carcinoma Immunotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396424000665

Similar Items

Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma
by: Grigorios Papadopoulos, et al.
Published: (2024-05-01)

Pharmacological SERCA activation limits diet-induced steatohepatitis and restores liver metabolic function in mice
by: Tomasz K. Bednarski, et al.
Published: (2024-06-01)

Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels
by: Mikkel B. Kjær, et al.
Published: (2025-02-01)

Gallic acid ameliorates diabetic steatohepatitis in db/db mice fed with a high-fat diet
by: Chi-Chih Wang, et al.
Published: (2025-03-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)

Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis
by: Paul Horn, et al.
Published: (2024-10-01)

Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression
by: Ana C. Maretti-Mira, et al.
Published: (2024-05-01)

Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems
by: Sonal Kumar, et al.
Published: (2024-07-01)

Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances
by: Ayana R. Kumar, et al.
Published: (2024-10-01)

Sleeve-gastrectomy results in improved metabolism and a massive stress response of the liver proteome in a mouse model of metabolic dysfunction-associated steatohepatitis
by: Andreas Kroh, et al.
Published: (2024-11-01)

The multifaceted roles of B lymphocytes in metabolic dysfunction–associated steatotic liver disease
by: Huige Li, et al.
Published: (2024-09-01)

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01)

Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yun Kyu Lee, et al.
Published: (2024-11-01)

Macrophage‐Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis
by: Tian Su, et al.
Published: (2024-11-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
by: Shyam Patel, et al.
Published: (2025-01-01)

Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
by: Parth Shah, et al.
Published: (2024-02-01)

Emerging therapies for MASLD and their impact on plasma lipids
by: Madison Nguyen, et al.
Published: (2024-03-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease
by: WANG Ziqian, et al.
Published: (2024-07-01)

Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
by: Jiaxin Chen, et al.
Published: (2024-06-01)

Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Rohit A. Sinha
Published: (2024-10-01)

Effects of Metabolic Dysfunction–Associated Steatohepatitis in Alertness, Associative Learning, and Astrocyte Density
by: Sara G. Higarza, et al.
Published: (2025-01-01)

Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Xue Zou, et al.
Published: (2024-12-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses
by: Èlia Navarro-Masip, et al.
Published: (2024-06-01)

Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma
by: Jiaxin Han, et al.
Published: (2024-09-01)

Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials
by: Hsin-Tien Ho, et al.
Published: (2024-10-01)

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Naim Alkhouri, et al.
Published: (2024-01-01)

Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease
by: Mohamed N. Abdelnabi, et al.
Published: (2024-08-01)

Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10
by: Yanying Yang, et al.
Published: (2024-11-01)

Epigenetic regulation of thyroid hormone action in human metabolic dysfunction-associated steatohepatitis
by: Alison-Michelle Naujack, et al.
Published: (2024-10-01)

Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease
by: Ziteng Wang, et al.
Published: (2024-12-01)

Relationship of Metabolic Dysfunction-Associated Steatohepatitis-Related Hepatocellular Carcinoma with Oral and Intestinal Microbiota: A Cross-Sectional Pilot Study
by: Takaaki Matsui, et al.
Published: (2024-07-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial
by: Apostolis Papaefthymiou, et al.
Published: (2024-10-01)

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
by: Qi Wang, et al.
Published: (2024-07-01)

Identification of Mitophagy-Associated Genes for the Prediction of Metabolic Dysfunction-Associated Steatohepatitis Based on Interpretable Machine Learning Models
by: Deng B, et al.
Published: (2024-05-01)

Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study
by: Minshan Huang, et al.
Published: (2024-08-01)

Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis
by: Zilu Cheng, et al.
Published: (2024-07-01)